Virocell launch on The Biomedical Scientist

Friday, 4 June 2021

Source: The Biomedical Scientist



ViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched. It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials. One of the founders of ViroCell is Farzin Farzaneh, Professor of Molecular Medicine at King’s College London, and it expects to employ more than 50 professionals in the UK by the end of 2021.